Boan Biotech Highlights Clinical Updates for BA6101 (biosimilar, Prolia) and BA1102 (biosimilar, Xgeva) to Treat Various Indications
Shots:
- The company has completed patient enrolment in P-III trial which evaluates the safety, efficacy, PK & immunogenicity of BA6101 & BA1102 vs reference drugs (Prolia & Xgeva) for the treatment of various indication across Europe, United States & Japan
- Boan had also conducted a meeting in Germany to highlight the PK results from the P-I analysis of BA6101 vs Prolia across Europe. The study met the pre-specified acceptance criteria of bioequivalence for PK & PD along with a similarity in PK, PD, safety & immunogenicity
- Earlier in Nov 2022, the company launched BA6101 (Boyoubei) across China and received positive feedback from doctors & patients on its clinical application. Later in Mar 2023, the NMPA accepted the BLA for BA1102
Ref: Boan Biotech | Image: Boan Biotech
Related News:- Boan Biotech Reports the Completion of Patient Enrolment in the P-III Clinical Trial of BA5101, a Proposed Biosimilar Dulaglutide
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
